



# Impact of particulate matter and air pollution on ocular surface disease: A systematic review of preclinical and clinical evidence

Sana Iqbal<sup>a,1</sup>, Abhishek Ramini<sup>b,1</sup>, Simon Kaja<sup>c,d,\*</sup> 

<sup>a</sup> Program in Molecular Pharmacology and Therapeutics, Loyola University Chicago, Maywood, IL, USA

<sup>b</sup> Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA

<sup>c</sup> Ophthalmology, Loyola University Chicago, Maywood, IL, USA

<sup>d</sup> Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, IL, USA

## ARTICLE INFO

### Keywords:

Particulate matter  
Dry eye  
Allergic conjunctivitis  
Ocular surface  
Air pollution

## ABSTRACT

**Purpose:** Exposure to particulate matter (PM) and air pollution has been implicated in the etiology of ocular surface diseases (OSD). The purpose of this systematic review is to evaluate and synthesize peer-reviewed literature on the impact of PM exposure on the ocular surface, integrating results from preclinical *in vitro* and *in vivo* studies with clinical findings to provide a comprehensive understanding of molecular mechanisms, physiological effects, clinical implications, and potential therapies to target acute and chronic PM-induced ocular toxicity.

**Methods:** A systematic literature search was performed using PubMed and EMBASE over the period from 2009 to 2024 following the recommendations for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. 102 studies were identified that met the inclusion/exclusion criteria. All studies were assessed for the risk of bias and qualitative data were analyzed.

**Results:** Preclinical studies using models of corneal and conjunctival cells found that exposure to PM and similar air pollutants resulted in apoptosis, primarily via inflammatory and oxidative stress pathways as well as allergic and immune responses. Animal models resulted in phenotypes reminiscent of that of dry eye disease, presenting with reduced tear volumes and ocular surface damage. These results were corroborated by clinical studies, which reported that patients commonly presented with symptoms of itching, burning, and irritation, and ocular surface signs correlated with a diagnosis of dry eye disease, conjunctivitis, and allergic eye disease.

**Conclusions:** This systematic review provides a comprehensive summary of our current understanding of PM exposure on the ocular surface, highlighting the correlation between exposure to PM and ocular surface dysfunction.

## 1. Introduction

Exposure to particulate matter (PM) as one of the major air pollutants has emerged as a significant public health concern in recent years due to its pervasive presence and wide-ranging adverse health effects. According to the World Health Organization, household air pollution alone was responsible for 3.2 million deaths globally per year in 2020, and the combined effects of ambient air pollution and household air pollution are associated with 6.7 million premature deaths annually [1]. Among the many organs affected by PM, the eyes are particularly vulnerable because they are directly exposed to the environment. The

ocular surface, which serves as the interface between the eye and our surrounding environment, is the primary barrier against external pollutants. The ocular surface is comprised of the cornea, conjunctiva, eyelids and eyelashes, the lacrimal and meibomian glands, and the tears [2]. Exposure to PM can lead to a variety of acute and chronic ocular surface diseases (OSD) [3,4]. Acute OSD typically includes allergic and irritant-induced conjunctivitis, while chronic sequelae present as dry eye syndrome, allergic conjunctivitis, and meibomian gland dysfunction [5–7]. Thus, there is an urgent need to develop a comprehensive understanding of the etiology of PM-induced OSD and strategies for developing novel targeted therapeutics.

\* Corresponding author. Loyola University Chicago, Stritch School of Medicine, Ocular Pharmacology and Drug Discovery Laboratory, 2160 S. First Ave., Maywood, IL 60153, USA.

E-mail address: [skaja@luc.edu](mailto:skaja@luc.edu) (S. Kaja).

<sup>1</sup> authors contributed equally.

<https://doi.org/10.1016/j.jtos.2024.12.003>

Received 29 July 2024; Received in revised form 3 December 2024; Accepted 9 December 2024

Available online 12 December 2024

1542-0124/Published by Elsevier Inc.

PM is a heterogeneous mixture of toxic pollutants that may be solid particles and liquid droplets suspended in the air. These particles vary in size, composition, and origin. They are frequently characterized by their diameter, where PM<sub>2.5</sub> refers to particles with a diameter of 2.5 µm or less, and PM<sub>10</sub> refers to particles with a diameter of 10 µm or less. Together, PM<sub>2.5</sub> and PM<sub>10</sub> are widely referenced as “fine atmospheric PM”. Carbon black is a component of PM composed primarily of elemental carbon in the form of fine particles. PM exposure can be from combustion processes such as vehicle emissions, diesel exhaust fumes, biomass combustion, military burn pits, and other industrial activities, natural sources like wildfires and volcanic eruption, or manmade sources like cigarette smoke and indoor fuel burning for cooking and heating.

*In vitro* studies provide crucial insights into the molecular mechanisms underlying the detrimental effects of PM exposure on the ocular surface and can identify cell-type specific responses following PM exposure. In contrast, preclinical *in vivo* studies allow for rigorous and standardized experimental designs to determine local effects on the ocular surface as a whole, including histopathological assessments, not possible in living organisms. Together, *in vitro* and *in vivo* preclinical studies can support the translation of novel therapeutic strategies to first-in-human trials.

Given the significant and growing body of evidence linking particulate matter to ocular surface diseases, the objective of the present study was to conduct a systematic review of preclinical and clinical studies of the effects of PM and air pollution exposure to the ocular surface. This comprehensive approach is crucial for identifying gaps in current knowledge, guiding future research directions, and informing clinical practices and public health policies aimed at protecting ocular health from the adverse effects of air pollution and toxic exposures.

## 2. Methods

### 2.1. Literature search

This systematic review followed a comprehensive search strategy to retrieve published articles following the recommendations for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines [8]. Two major databases, PubMed and EMBASE, were searched to identify peer-reviewed original articles on PM and OSD in the past 15 years, from January 01, 2009 to January 19, 2024. The following search items were used: particulate matter AND ocular OR particulate matter AND ocular surface OR pollution AND ocular OR pollution AND ocular surface. Search terms were queried in both databases. This review was not registered.

### 2.2. Inclusion and exclusion criteria

Articles were included in this systematic review if they met the following inclusion criteria: (1) studies in English, (2) published in the last 15 years (starting 2009), (3) articles in peer-reviewed scientific journals, and (4) preclinical studies in human and non-human models and clinical studies (interventional and observational).

The following articles and article types were excluded: (1) meta-analysis, review, and systematic review, and (2) studies in languages other than English.

### 2.3. Data collection

Two reviewers (S.I. and A.R.) independently conducted the literature search based on the predetermined search terms. Records were imported into Excel and duplicates were removed. Titles and abstracts were searched manually, and relevant articles had to meet the above inclusion/exclusion criteria and address the objectives of this systematic review. Any discrepancies were resolved by discussion and if needed, consultation with a third reviewer (S.K.). Full text versions of all

potential studies were retrieved.

### 2.4. Data extraction and synthesis

The following data were extracted: (1) study characteristics and (2) study outcomes. Data were tabulated and compared with other pre-clinical or clinical studies.

### 2.5. Risk of bias

To assess bias in the included studies, the SYRCLE risk of bias tool was used for *in vivo* studies based on the Cochrane Collaboration's tool for assessing risk bias in randomized trials [9,10]. For *in vitro* studies, a modified SYRCLE risk of bias tool was used [11]. For non-randomized clinical studies, the Risk-of-Bias In Non-Randomized Studies of Exposure (ROBINS-E) tool was used for observational studies [12]. Finally, the Cochrane Risk-of-bias tool 2.0 (RoB 2.0) was used for the single interventional study [13]. Bias assessments were carried out by 2 independent reviewers (S.I. and A.R.) and any discrepancies were resolved after discussion. All risk of bias assessments were plotted using the robvis visualization tool [14].

### 2.6. Statistical analysis

Descriptive statistics were used to characterize the studies included in the analysis. Due to insufficient quantitative data, conducting a meta-analysis was not feasible. Therefore, a qualitative comparison between studies was performed.

## 3. Results

### 3.1. Study selection

A systematic search initially identified 946 records, of which 426 were from PubMed and 520 were from EMBASE (Fig. 1). 231 duplicate records were removed, and the remaining 715 records were screened for inclusion and exclusion criteria. Finally, 194 records were sought for retrieval and assessment. 92 studies were excluded after full-text screening. Ultimately, 102 studies were included in the qualitative systematic review and analyzed based on their classification type of (1) *in vitro*, (2) *in vivo*, or (3) clinical.


### 3.2. Preclinical models

Preclinical studies originated from around the world and used various types of air pollutants. The primary type of pollutant used for the included studies was particulate matter of varying sizes, as described in 25 out of 44 (57%) studies [15–39]. Other types of pollutants included carbon black, urban dust, cigarette smoke, wood smoke, diesel exhaust fumes, and volcanic ash. These pollutants were sourced from a variety of locations, including self-collected from the site of research or commercially purchased. Given the varying composition of the PM and related pollutants used, varying doses and routes were implemented to model exposure in these preclinical models. The characteristics of these studies are summarized in Table 1.

*In vitro* models primarily consisted of corneal epithelial cells exposed to PM or similar pollutants in 20 out of 25 (80%) *in vitro* studies [16,18,19,22–25,30–32,35,36,38–45]. 7 of 25 (28%) *in vitro* studies used conjunctival epithelial cells [21,30,42,45–48]. Additional models included both corneal and conjunctival epithelial cells [30,42,45] and a reconstructed 3D human corneal epithelial tissue model with stratified corneal epithelial cells [25]. For almost all studies, *in vitro* exposure consisted of adding PM or similar pollutants directly into the cell culture medium, except for Karakoçak et al. who performed both a liquid and gas phase exposure [40].

*In vivo* models primarily consisted of C57BL/6 J and BALB/c mice in

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

Fig. 1. PRISMA 2020 flow diagram of included studies.

11 out of 31 (35%) [17,26,32,38,39,41,43,44,49–51] and 7 out of 31 (23%) [20,28,36,52–55] *in vivo* studies respectively. Sprague-Dawley rats were also commonly used in 8 out of 31 (26%) *in vivo* studies [21, 22,27,29,31,33,34,56]. Almost all studies used rodent models, except single zebrafish study [57], and a study by Ghosh et al. who were the first to describe the toxic effects of PM on the ocular surface and therapeutic efficacy of drug candidates and therapeutics in New Zealand White rabbits [18]. 20 out of 31 (65%) *in vivo* studies applied PM or other pollutants directly into the eye [17,18,20–22,26–28,31–34,36–38, 44,49,51,52,57], whereas the remaining 11 out of 31 (35%) used air-forced chambers [15,29,39,41,43,50,53–56,58].

### 3.3. Molecular mechanisms and phenotypes identified following exposure to preclinical models

Most selected articles identified oxidative stress, inflammatory pathways, and apoptosis implicated in PM-induced ocular pathophysiology (Table 1, Suppl. Table 2). Further mechanisms identified included changes to mucin expression [44,45,53,57] and allergic and immune responses [17,20,26,37,54].

Upon exposure to PM, *in vivo* models recapitulated varying degrees of OSD phenotypes manifesting as, most commonly, a decrease in tear volume and tear film stability, and increases in corneal fluorescein staining, inflammation, and the overall presence of dry eye symptoms (Table 1, Suppl. Table 3).

### 3.4. Pharmacological targeting of PM-induced ocular toxicity

13 out of the 44 preclinical articles (30%) tested a drug candidate or therapeutic for PM-induced ocular toxicity in both *in vitro* and *in vivo* models either concurrently or following discontinuation of PM exposure

(Table 2). The therapies tested targeted proteins or genes implicated in PM-induced toxicity, such as a sirtuin 1 (SIRT1) activator [30], granulocyte-macrophage colony-stimulating factor (GM-CSF) inhibitor [23], or necrostatin-1 (Nec-1), a specific inhibitor of necroptosis [44]. Several therapies were derived from medicinal herbs [15,21,33,34,57], and all treatments had evidence of some antioxidant and anti-inflammatory properties. Furthermore, all therapies demonstrated some level of protective effects and mitigated PM-induced toxicity to some extent.

### 3.5. Preclinical risk of bias assessment

The risk of bias assessments is presented in Suppl. Table 4 and Fig. 2a–b for *in vitro* studies. Across all categories, the overall quality was considered high, with a median  $\pm$  interquartile range of 16 (2). All studies clearly defined the type of environmental pollutant used and the context of its use. Furthermore, all studies clearly defined *in vitro* methodology, including the cell material and specification of materials and media used. Some studies did not clearly indicate exposure or exposure modeling, and several studies demonstrated medium or no compliance with experimental robustness and randomization or blinding (Fig. 2a). Overall, the *in vitro* studies detailed full or medium compliance for criteria of robustness and downstream application; however, nearly 33% and 24% showed no compliance or medium compliance respectively for reproducibility (Fig. 2b).

The risk bias assessments are presented in Fig. 3 for *in vivo* studies. Most studies (65%) detailed randomization and baseline characteristics of the cohort. Only 23% and 26% of the studies stated blinding of participants and blinding of outcomes assessments, respectively, in their methodology. Most studies were high risk for or did not state details about allocation concealment, random housing, random outcome

**Table 1**  
Characteristics of preclinical studies.

Study	Type of pollutant studied	Source of pollutant	Type of ocular surface disease studied	Acute or chronic exposure	Study type	Study model	Exposure dose	Exposure route	Key Results
<b>Particulate Matter (PM<sub>2.5</sub>, PM<sub>4</sub>, PM<sub>10</sub>, PM, Urban PM, Other PM)</b>									
Ko et al. [25]	PM <sub>0.3-2.4</sub> , PM <sub>&gt;2.4</sub>	Fukuoka, Japan	Not specified	Not specified	<i>in vitro</i>	Reconstructed human corneal epithelium model HCECs	0–100 µg/mL for 24 h	Added to cell culture media	Decreased HCE viability and ZO-1 expression Significant decrease in cell viability
Fu et al. [16]	PM <sub>2.5</sub>	Hangzhou, China	Not specified	Acute	<i>in vitro</i>	BALB/C mice	0.1–1 mg/mL b.i.d for 7 days	Topical	Th2-dominant immune response, leading to exacerbation of ocular allergic inflammation and enhanced dendritic cell maturation at 5 mg/mL
Hwang et al. [20]	PM <sub>2.5</sub>	Road dust from Seoul, Korea	Ocular allergic inflammation	Not specified	<i>in vivo</i>	HCECs	5–200 µg/mL for 48 h	Added to cell culture medium	Reduced HCEC survival and inflammatory cytokine release
Kashiwagi et al. [23]	PM <sub>2.5</sub>	NIST SRM 1650b	Ocular surface damage	Not specified	<i>in vitro</i>	Rat CECs	25–300 µg/mL for 24h	Added to cell culture medium	PM <sub>2.5</sub> exposure leads to ROS/p38 MAPK/NF-κB signaling pathway and leads to mitochondrial damage and DNA double-strand break
Kim et al. [24]	PM <sub>2.5</sub>	Road dust from Seoul, Korea	Dry eye disease or allergies	Not specified	<i>in vivo</i>	C57BL/6 mice	0.5 mg/mL b.i.d 14 days	Topical	Increase in CFS, proinflammatory cytokines, serum IgE, Th2, epithelium toxicity
Lee et al. [26]	PM <sub>2.5</sub>	NIST SRM 1650b	Dry eye disease	Not specified	<i>in vivo</i>	Sprague-Dawley rats	5 mg/mL q.i.d for 2 weeks	Topical	Reduction of tear secretion, corneal epithelial damage, over-expression of pro-inflammatory cytokines
Lee et al. [27]	PM <sub>2.5</sub>	Center for Disease Control and Prevention of Zhejiang Province, Hangzhou, Zhejiang, China	Dry eye disease	Acute	<i>in vitro</i> and <i>in vivo</i>	HCECs and Sprague-Dawley rats	25–100 µg/mL for 24 h <i>in vitro</i> , 1 mg/mL q.i.d. for 21 days <i>in vivo</i>	Added to cell culture medium, topical	Upregulation of PAI-2 expression. Increased CFS and reduced tear secretion
Lyu et al. [31]	PM <sub>2.5</sub>	Chengguan Distrcit, Lanzhou, China	Ocular surface damage	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCECs and C67BL/6 mice	25–400 µg/mL for 48 h <i>in vitro</i> , 1 mg/mL t.i.d. 3 months <i>in vivo</i>	Added to cell culture medium, topical	ROS formation and NLRP3 inflammasome-mediated pyroptosis axis
Niu et al. [32]	PM <sub>2.5</sub>	Beijing	Dry eye disease	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCE-T and C57/BL	Increasing doses (40–200 mg/mL) <i>in vitro</i> for 24–48 h, 200 µg/mL up to 10 weeks <i>in vivo</i> .	Added to cell culture medium, air forced chambers	Mitochondrial dysfunction, inhibition of Nrf2, activation of P65
Yu et al. [39]	PM <sub>2.5</sub>	Hangzhou	Ocular surface damage	Not specified	<i>in vitro</i>	HCECs	50–200 µg/mL for 24 h	Added to cell culture medium	Long noncoding RNAs RP3-406P24.3 and RP11-285E9.5 are involved in the biological processes and pathogenic pathways of PM-induced ocular surface damage
Song et al. [35]	PM <sub>2.5</sub>								

(continued on next page)

Table 1 (continued)

Study	Type of pollutant studied	Source of pollutant	Type of ocular surface disease studied	Acute or chronic exposure	Study type	Study model	Exposure dose	Exposure route	Key Results
Tan et al. [36]	PM <sub>2.5</sub>	Xi'an environmental monitoring station	Dry eye syndrome	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCEC and BALB/c mice	5 mg/ml PM <sub>2.4</sub> for up to 8 h <i>in vitro</i> , 5 mg/mL q.i.d. for 14 days <i>in vivo</i> .	Added to cell culture medium, topical	Significant decrease in tear volume, TBUT, corneal epithelial microvilli and corneal desmosomes. Apoptosis and increased expression of proinflammatory cytokines.
Tang et al. [37]	PM <sub>2.5</sub>	Taichung city, Taiwan	Allergic conjunctivitis	Chronic	<i>in vivo</i>	ICR mice	3.2–12.8 mg/mL, t.i.d. for 19 days	Topical	More eyelid edema, tearing, and scratching behaviors, with increased TBUT, higher goblet cell density and eosinophil infiltration $\geq 3.2$ mg/mL
Ghosh et al. [18]	PM <sub>4</sub>	NIST SRM 2786	Dry eye disease	Not specified	<i>in vitro</i> and <i>in vivo</i>	SIRC and New Zealand White Rabbits	1–300 µg/mL for 24 h <i>in vitro</i> , 5 mg/mL <i>in vivo</i> t.i.d. for up to 10 days	Added to cell culture media, topical.	Dose-dependent cell death and impaired cell motility, hyperemia, increased CFS, and decreased tear volume
Yang et al. [38]	PM <sub>4</sub>	NIST SRM 2786	Ocular surface damage	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCECs and C57BL/6 mice	0.1 mg/mL and 0.2 mg/mL for 12 or 14 h <i>in vitro</i> , 0.5–5 mg/mL q.i.d. for 6 months <i>in vivo</i>	Added to cell culture medium, topical	Increased inflammatory cytokines, elevated ROS generation, and cellular apoptosis, reduced TBUT, damage to conjunctiva $\geq 0.5$ mg/mL
Li et al. [28]	PM <sub>10</sub>		Dry eye disease	Not specified	<i>in vivo</i>	BALB/c mice	5 mg/mL q.i.d. for 14 days	topical	Increased CFS, decreased tear volume, corneal epithelial microvilli, corneal chondriosome/desmosome. Apoptosis and increased levels of proinflammatory cytokines.
Guerra-Flórez et al. [19]	PM	Medellin, Colombia	Not specified	Not specified	<i>in vitro</i>	Rabbit corneal epithelial cells (SIRC) and a microphysiologic two-cell layer system.	1–5 mg/mL for 24 h	Added to cell culture medium	Multilayer models are more resistant to PM exposure than monolayer models. Fine PM is more cytotoxic than coarse PM.
Fukase et al. [17]	PM, Asian dust	NIES, Japan	Allergic conjunctivitis	Not specified	<i>in vivo</i>	C57BL/6 mice	0.5 mg suspended in 2.5 µL	Topical	Increased eosinophil infiltration, no change in neutrophil infiltration
Hyun et al. [21]	Urban PM	NIST SRM 1648a	Keratoconjunctivitis Sicca	Not specified	<i>in vitro</i> and <i>in vivo</i>	Conjunctival epithelial cells and Sprague-Dawley rats	100 µg/mL for 24 h <i>in vitro</i> and 20 mg/mL t.i.d. for 5 days <i>in vivo</i>	Added to cell culture media, topical	Increased release and expression of TNF-α and IL-6, reduction of tear secretion, corneal epithelial damage, disruption of mucin-4
Hyun et al. [57]	Urban PM	NIES No. 28	Ocular surface damage	Not specified	<i>in vitro</i> and <i>in vivo</i>	zebrafish, EA.hy926 cells	0.001–0.1 % PM in water, 3–100 µg/mL PM in cell culture medium	Added to cell culture medium, added to water of zebrafish embryo	Fatal malformation in the integuments of zebrafish, increased vascular diameter, increased cell migration and capillary-like structure formation, and angiogenesis
Kang et al. [22]	Urban PM	NIST SRM 1648a	Ocular surface damage	Chronic	<i>in vitro</i> and <i>in vivo</i>	HCE cells and Sprague-Dawley rats	0–1000 µg/mL for 24 h <i>in vitro</i> , 5 mg/mL q.i.d.	Topical, added to cell	Decreased cell migration and survival, and

(continued on next page)

Table 1 (continued)

Study	Type of pollutant studied	Source of pollutant	Type of ocular surface disease studied	Acute or chronic exposure	Study type	Study model	Exposure dose	Exposure route	Key Results
Li et al. [30]	Urban PM	NIST 1648a	Ocular surface damage	Acute	<i>in vitro</i>	HCEC and HCjECs	for 16 weeks <i>in vivo</i> 100–1000 µg/mL for 24 h	culture media Added to cell culture medium	consistently increased fluorescein scores ROS production, decreased SIRT1 expression.
Park et al. [33]	Urban PM	NIST SRM 1648a	Dry eye disease	Not specified	<i>in vivo</i>	Sprague-Dawley rats	20 mg/mL t.i.d for 5 days	Topical	Tear hyposecretion, corneal irregularity, apoptotic injury of lacrimal gland
Shi et al. [44]	Urban PM	NIST 1649b	Ocular surface damage	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCECs and C57BL/6 mice	50–150 µg/mL for 16 h <i>in vitro</i> , and 2 mg/mL q.i.d <i>in vivo</i> .	Added to cell culture medium, topical	PM-induced necroptosis, inducing corneal inflammation and decreased mucin production.
Song et al. [34]	Urban PM	NIST SRM 1648a	Dry eye syndrome	Not specified	<i>in vivo</i>	Sprague-Dawley rats	1 mg/mL - 10 mg/mL t.i.d for 10 days	Topical	Decreased tear volume, corneal epithelial irregularity and damage, disruption of corneal mucin-4 layer $\geq 1$ mg/mL
Maglione et al. [53]	Urban air	Buenos Aires City	Ocular mucosa	Chronic	<i>in vivo</i>	BALB/c mice	5 L/min for up to 12 months	Air forced chambers	Alterations in mucin-positive cells and increased IL-6 levels
Sendra et al. [54]	Urban airflow and indoor airflow	Buenos Aires city	Immune responses	Not specified	<i>in vivo</i>	BALB/c mice	8 h per day	Air forced chambers	Development of a severe form of herpes simplex keratitis with increased corneal opacity, neovascularization, HSV-1 DNA and production of proinflammatory cytokines. Activation of dendritic cells.
Vitar et al. [55]	Urban air	Buenos Aires city	Ocular surface damage	Not specified	<i>in vivo</i>	BALB/c mice	Urban air for 8 h/day, 5 days/week up to 12 weeks	Air forced chambers	Increase in antioxidant enzymes after 1 week, redox imbalance, proinflammatory cytokines
<b>PM from combustion</b>									
Akintunde et al. [15]	Wood smoke and PM <sub>10</sub>	Melina wood	Ocular surface damage	Subchronic	<i>in vivo</i>	Albino rats	441.2 µg/m <sup>3</sup> PM <sub>10</sub> from wood smoke, 20 min, q.d. for 21 days	Air forced chambers	Inflammation, alterations in antioxidant enzyme concentration, and cell damage
Karakoçak et al. [40]	Applewood and coal combustion	Commercially available sources	Toxicity on ocular cells	Acute	<i>in vitro</i>	Corneal, lens, and retinal epithelial cells	3 L per minute or 10–1000 µg/mL for 1 h	Gas phase exposure and liquid phase exposure.	Coal emission had more toxic effect than applewood emission on ocular cells, with decreased cell viability and increased ROS generation.
<b>Cigarette and tobacco smoke</b>									
Jin et al. [49]	Cigarette smoke extract	Commercial cigarette	Ocular surface damage	Not specified	<i>in vivo</i>	C57/BL6J mice	1–5 % V/V q.d. for 1 week	Topical	Disruption of the structural integrity of the superficial epithelium, decreased the density of microvilli, and compromised the corneal epithelial barrier intactness $\geq 1$ % V/V
Kojima et al. [50]	Sidestream cigarette smoke	Seven Stars	Ocular surface damage	acute	<i>in vivo</i>	C57BL/6 Wildtype and Nrf2 knockout mice	1 lit cigarette every 30 min, 6 times in 3 h for 5 days	Air forced chamber	Decreased tear stability, ocular surface damage, and altered conjunctival phenotype for Nrf2

(continued on next page)



Table 1 (continued)

Study	Type of pollutant studied	Source of pollutant	Type of ocular surface disease studied	Acute or chronic exposure	Study type	Study model	Exposure dose	Exposure route	Key Results
Li et al. [41]	Cigarette smoke	Marlboro cigarettes	Dry eye disease	Chronic	<i>in vitro</i> and <i>in vivo</i>	HCECs and c57BL mice	Dilutions of DMSO lipid-soluble cigarette smoke particles equivalent of 3 cigarettes <i>in vitro</i> , equivalent of 8 cigarettes for 4 or 12 weeks <i>in vivo</i>	Added to cell culture medium, air forced chambers	knockout over wildtype Presence of dry eye symptoms, corneal and conjunctival damage, increase of apoptosis and Ki67. Proinflammatory cytokine release
Miao et al. [43]	Cigarette smoke extract	Marlboro cigarettes	Ocular surface damage	Not specified	<i>in vitro</i> and <i>in vivo</i>	HCECs and C57BL/6 mice	1.5 % cigarette smoke extract up to 6 h <i>in vitro</i> , 50 mL smoke every 30 min, 6 times for up to 3 days <i>in vivo</i> .	Added to cell culture medium, air forced chambers	Reduced cell viability, increased apoptotic cells, elevated intracellular oxidative stress and loss of mitochondrial transmembrane potential, autophagy
Xiao et al. [58]	Tobacco smoke	Malboro	Corneal wounds	Acute	<i>in vivo</i>	NFκB1 mutated mice	3 lit cigarettes in 90 min, twice 12 h apart	Air forced chamber	Increased levels of epinephrine and norepinephrine, enhanced inflammatory responses, delayed wound healing, and altered immune cell populations in the cornea
<b>Carbon black</b>									
Jiao et al. [52]	Carbon black	Extracted from PM <sub>2.5</sub> from Beijing	Dry eye disease	Not specified	<i>in vivo</i>	BALB/C mice	0.5 mg/mL - 5 mg/mL t.i.d for 2 weeks	Topical	Decreased tear film stability, reduced tear secretion, ocular surface damage ≥0.5 mg/mL
Li et al. [56]	Carbon black	Orion Engineered Carbons	Ocular injury	Not specified	<i>in vivo</i>	Sprague-Dawley rats	160 µg/m <sup>3</sup> for 2 h b.i.d. for 5 days	Air forced chambers	Increased CFS, LDH activity, serum IgG and IgE, cervical lymph nodes, IK-4, IFN-γ
Li et al. [29]	Carbon black, PM <sub>10</sub>	Orion Engineered Carbons	Ocular surface damage	Not specified	<i>in vivo</i>	Sprague-Dawley rats	160 µg/m <sup>3</sup> for 5 days	Air forced chambers	Increase in ocular surface staining scores, tear LDH activity, tear MMP-9, histamine, and lactoferrin concentrations, and the expression of IL-4 and IFN-γ
<b>Diesel exhaust particles</b>									
Tau et al. [45]	Diesel exhaust particles	Sao Paulo, Brazil	Not specified	Not specified	<i>in vitro</i>	corneal epithelial cells (HCLE) and conjunctiva epithelial cells (IOBA-NHC)	10–500 µg/mL for 24 h	Added to cell culture medium	Cytotoxicity and inflammatory response, increase in mucin expression in cornea and conjunctiva
Vitar et al. [47]	Diesel exhaust particles	Sao Paulo, Brazil	Not specified	Not specified	<i>in vitro</i>	Human conjunctival epithelium cell line	10–100 µg/mL for 24 h	Added to cell culture media	Increased levels of reactive oxygen species (ROS), reactive nitrogen species (RNS), hydrogen peroxide
Vitar et al. [48]	Diesel exhaust particles	Sao Paulo, Brazil	Not specified	Not specified	<i>in vitro</i>	Conjunctival epithelial cells	100 µg/mL for up to 24 h	Added to cell culture medium	Early redox imbalance followed by an IL-6 mediated inflammatory response, with

(continued on next page)

Table 1 (continued)

Study	Type of pollutant studied	Source of pollutant	Type of ocular surface disease studied	Acute or chronic exposure	Study type	Study model	Exposure dose	Exposure route	Key Results
Yang et al. [51]	Diesel exhaust particles	NIST SRM 2975	Ocular surface damage	Not specified	<i>In vivo</i>	C57BL/6 mice	100 and 1000 µg/mL b.i.d. for up to 28 days	Topical	involvement of mitochondrial superoxide anion and NADPH oxidase-4 Increased corneal epithelial permeability, alterations in corneal epithelial cell layers, Ki67 expression. Reduced goblet cells in the conjunctival fornix, and apoptotic cells in the corneal and conjunctival epithelium. Increased CD4 <sup>+</sup> cells and NFκB expression in conjunctiva ≥100 µg/mL
<b>Other PM sources</b>									
Li et al. [42]	Titanium dioxide (TiO <sub>2</sub> ) NPs, carbon black (CB) NPs, and silicon dioxide (SiO <sub>2</sub> )	Commercial suppliers	Ocular surface damage	Not specified	<i>in vitro</i>	HCECs and HCjECs	12.5–400 µg/mL for 24 h	Added to cell culture medium	Toxic effects were more severe in HCECs than HCjECs, increased ROS, leading to apoptosis and mitochondrial damage
Tesone et al. [46]	Volcanic ash	Puyehue-Cordon Caulle Volcanic Complex	Not specified	Not specified	<i>in vitro</i>	Conjunctival epithelial cells	50–1000 µg/mL for 24 h	Added to cell culture medium	Reduced cell proliferation, increased pro-inflammatory cytokines

Table 1 Abbreviations: HCEC: Human corneal epithelial cells, h: hours, NIES: National Institute for Environmental Studies, NIST: National Institute for Standards and Technology, SRM: Standard Reference Materials, t.i.d.: ter in die (three times a day), b.i.d.: bis in die (two times a day), q.d.: quaque die (once a day), q.i.d.: quater in die (four times a day), CRM: Certified Reference Materials, Nrf2: Nuclear factor (erythroid-derived 2)-like 2, HCjECs: Human Conjunctival Epithelial Cells, NFκB1: Nuclear Factor Kappa B Subunit 1.

assessment, and selective outcome reporting (Fig. 3).

3.6. Clinical studies

A summary of key characteristics (geographic location, study population, type of pollutant(s) studied, method of pollutant exposure measurement, type of ocular surface disease studied/symptoms, method of ocular surface disease/symptoms diagnosis or evaluation) of all clinical studies assessed in this review are represented in Table 3. The results of the studies assessed are briefly summarized below.

3.7. Ocular surface signs and symptoms

Several studies in school children investigated general ocular symptoms, such as itching, burning, irritation, and tearing in response to PM<sub>2.5</sub> and PM<sub>10</sub> [59–62], as well as other airborne irritants [63,64]. Generally, exposure to PM was positively correlated with ocular surface symptoms. Similar findings were obtained in various studies in adult populations across differing geographical locations and social or occupational exposures [65–74]. Overall, most studies demonstrated that levels of PM and other airborne pollutants such as NO<sub>2</sub>, O<sub>3</sub>, SO<sub>2</sub> were significantly correlated with incidence and/or severity of varying ocular surface symptoms. Presence of DED has been found to significantly associated with NO<sub>2</sub> [75,76] and O<sub>3</sub> but not with SO<sub>2</sub> or PM<sub>10</sub> [76], supported by significant correlations between PM<sub>2.5</sub>, PM<sub>10</sub>, and NO<sub>2</sub> and biomarkers for meibomian gland disease and inflammation [77–81]. Similarly, ocular surface signs such as tear break-up time (TBUT), lipid layer thickness (LLT),


mucus quality and composition, Schirmer’s test, were associated positively with PM levels and other airborne pollutants [82–85]. Pollutants had similar effects in patients with Sjögren’s disease and those with MGD [83]. While Matsuda et al. reported that air pollutants including PM<sub>2.5</sub> alter the ocular surface through perturbations in mucus quality [84], Toricelli et al. did not observe any significant correlation between levels of NO<sub>2</sub> or PM<sub>2.5</sub> and OSDI scores or MUC5AC mRNA expression [86]. The same group observed a negative correlation between tear osmolarity level and PM<sub>2.5</sub> levels but not NO<sub>2</sub>; similarly OSDI, TBUT, Schirmer test, and vital staining scores were not significantly correlated with PM<sub>2.5</sub> or NO<sub>2</sub> levels [87]. Blepharitis-associated eyelid debris was significantly correlated CO, NO<sub>2</sub>, and PM<sub>10</sub> exposure, while NO<sub>2</sub> exposure was linked to increased MG secretion [88]. Several studies reported paradoxical findings, while others demonstrated that associations between particulate matter exposure and ocular surface signs and symptoms were notably affected by confounding variables, including temperature and humidity [89,90], consistent with studies that evaluated the impact of indoor environment [91,92]. 3.8. Conjunctivitis and allergic eye disease Several studies found differential associations between CO, PM<sub>2.5</sub>, PM<sub>10</sub>, NO, NO<sub>2</sub>, O<sub>3</sub>, and SO<sub>2</sub> with incidence of conjunctivitis, vernal keratoconjunctivitis, diagnosis and outpatient visits for allergic conjunctivitis, and acute microsporidial keratoconjunctivitis (MKC) [93–102]. Nucci et al. reported the association between pediatric conjunctivitis of unknown origin and higher levels of PM<sub>10</sub>, but did not



**Table 2**  
Preclinical studies testing therapies to mitigate PM-induced toxicities.

Study	Type of pollutant studied	Study model	Exposure dose	Therapy tested	Therapy dose and route	Description of therapy	Effects of therapy
Akintunde et al. [15]	Wood smoke and PM <sub>10</sub>	Albino rats	441.2 µg/m <sup>3</sup> PM <sub>10</sub> from wood smoke, 20 min, q.d. for 21 days	Naringin	80 mg/kg/d oral, cotreated with exposure for 21 days	Naturally-derived bioactive flavanone glycoside	Protective against wood smoke-induced ocular damage
Ghosh et al. [18]	PM <sub>4</sub>	SIRC and New Zealand White Rabbits	1–300 µg/mL for 24 h <i>in vitro</i> , 5 mg/mL <i>in vivo</i> t.i.d. for up to 10 days	Two separate treatments: Mn-TM-2-PyP or lifitegrast	0.05 % w/v Mn-TM-2-PyP or 5 % ophthalmic lifitegrast, topical, for 10 days after discontinuation of PM exposure	Mn-TM-2-PyP, a synthetic antioxidant, and lifitegrast.	Both treatments improved hyperemia and CFS. Efficacy of Mn-TM-2-PyP was greater compared with lifitegrast.
Hyun et al. [21]	Urban PM	Conjunctival epithelial cells and Sprague-Dawley rats	100 µg/mL for 24 h <i>in vitro</i> and 20 mg/mL t.i.d. for 5 days <i>in vivo</i>	Apricot kernel extract and amygdalin	0.5 or 1 mg/mL topical q.d. for 5 days after exposure	Extract from the seed of <i>Prunus armeniaca</i> (apricot)	Attenuate corneal epithelial damage and reduction of tear secretion, and prevention of MMP9 and proinflammatory cytokines
Hyun et al. [57]	Fine dust	zebrafish, EA. hy926 cells	0.001–0.1 % PM in water, 3–100 µg/mL PM in cell culture medium	α/β adenosine	0.3–3 µg/mL added to water or cell culture medium	Isolated from the anti-angiogenic brown algae <i>Ishige okamurae</i> extract	Protective against angiogenesis
Kashiwagi et al. [23]	PM <sub>2.5</sub>	HCECs	5–200 µg/mL for 48 h	Suramin	1 or 5 µM added to cell culture medium simultaneously	Suramin, a GM-CSF inhibitor	Alleviated HCEC impairment
Lee et al. [27]	PM <sub>2.5</sub>	Sprague-Dawley rats	5 mg/mL q.i.d. for 2 weeks	Spermidine, cyclosporin A	0.2 % and 0.5 %, topical, q.i.d. 30 mins after PM exposure for Spermidine. 0.05 % Cyclosporin N.	Spermidine, cyclosporine A	Attenuated reduction of tear secretion and corneal epithelial damage
Li et al. [56]	Carbon black	Sprague-Dawley rats	160 µg/m <sup>3</sup> for 2 h b.i.d. for 5 days	diquafosol	3 % topical 6 times a day during exposure	Diquafosol, a mucin secretagogue	Protective effect, increased tear MUC5AC concentration and decreased tear LDH activity.
Li et al. [29]	carbon black, PM <sub>10</sub>	Sprague-Dawley rats	160 µg/m <sup>3</sup> for 5 days	Eyebon-W eye wash	1 mL irrigation for 30 s after exposure (twice daily)	Commercial eye wash solution containing anti-inflammatory and antihistamine agents.	Reversed elevation of IL4, IFNγ, ocular staining scores, tear LDH activity, histamine and MMP-concentrations in tear fluid
Li et al. [30]	Urban PM	HCEC and HCjECs	100–1000 µg/mL for 24 h	SRT1720	2.5 µM for 24 h with PM exposure	SRT1720, a SIRT1 activator	Upregulated SIRT1 expression and inhibited ROS production
Miao et al. [43]	Cigarette smoke extract	HCECs and C57BL/6 mice	1.5 % cigarette smoke extract up to 6 h <i>in vitro</i> , 50 mL smoke every 30 min, 6 times for up to 3 days <i>in vivo</i> .	cysteamine	250 µM <i>in vitro</i> , 0.55 % in PBS topical pretreatment <i>in vivo</i>	Cysteamine, an antioxidant and inducer of autophagy	Attenuated cell damage, oxidative stress and mitochondrial dysfunction; rescued <i>in vivo</i> phenotype.
Park et al. [33]	Urban PM	Sprague-Dawley rats	20 mg/mL t.i.d. for 5 days	Aucubin	0.1 % and 0.2 %, topical t.i.d. 30 mins after exposure for an additional 5 days	Aucubin, isolated from a traditional medicinal herb, <i>Aucuba japonica</i>	Attenuated tear hyposecretion, corneal irregularity, and apoptotic injury of lacrimal glands
Shi et al. [44]	Urban PM	HCECs and C57BL/6 mice	50–150 µg/mL for 16 h <i>in vitro</i> , and 2 mg/mL q.i.d. <i>in vivo</i> .	Nec-1	5 mg/kg intraperitoneally q.d. with PM exposure	Necrostatin-1, specific inhibitor of necroptosis	Inhibition of the increased inflammatory cytokines and the decreased mucin expression. Reduced corneal inflammation and mucin underproduction in mouse ocular surface
Song et al. [34]	Urban PM	Sprague-Dawley rats	1 mg/mL - 10 mg/mL t.i.d. for 10 days	<i>Liriope platyphylla</i> extract	10 mg/mL topical t.i.d. for 9 days with exposure. On final day, administered once.	Extract from <i>Liriope platyphylla</i> , a perennial herbaceous evergreen of the lily family.	Attenuated decrease in tear volume and reduced corneal epithelial irregularity and damage; protected against disruption of the corneal mucin-4 layer and reduction in the conjunctival goblet cell density

**Table 2** Abbreviations: q.d.: quaque die (once a day), h: hours, t.i.d.: ter in die (three times a day), Mn-TM-2-PyP: Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, CFS: Corneal Fluorescein Staining, MMP: Matrix metalloproteinases, HCEC: Human corneal epithelial cells, GM-CSF: Granulocyte-macrophage colony-stimulating factor, q.i.d.: quater in die (four times a day), ROS: Reactive Oxygen Species, b.i.d.: bis in die (two times a day), MUC5AC: Mucin-5AC, HCjECs: Human Conjunctival Epithelial Cells, SIRT1: Sirtuin 1.



**Fig. 2. Risk of bias assessment of *in vitro* studies.** (A) Study compliance with validation metrics as evaluated in Suppl. Table 4 using a modified SYRCLE risk of bias tool. (B) Study compliance with validation criteria categorically presented. The following domains were assessed: 1) Does the study use (an) appropriate compound(s) to stimulate the desired outcome(s)? 2) Is there a clear definition of the relevance of the test method, making clear the relationship of the test method to the outcome(s) of interest? 3) Does the study make use of data for the outcome(s) for defined reference compounds (positive and negative controls). Are the concentration ranges tested included? 4) Is there a full description of cell or tissue source(s), are quality checks included? (e.g., viability, functional performance tests, metabolic activity). 5) Does the study detail drug stability data and determination of exposure? (total/unbound, ideally also intracellular concentrations). 6) Is there a detailed description of materials with regards to drug interactions? 7) Has there been an attempt to model the *in vitro-in vivo* extrapolation of the drug response? 8) Was the study carried out according to clear protocols? Is there available documentation suitable for a GLP-style environment i.e. commercial assay? 9) Is there a demonstration of intra-lab or multi researcher repeatability? (There would also ideally be demonstration of inter-laboratory comparative data). 10) Is there mention of attempts to reduce investigator bias including randomization and/or blinding?.

observe any association with PM<sub>2.5</sub> levels [103].

### 3.9. Associations between particulate matter exposure and ocular disease

Three studies evaluated the possible association between toxic particulate exposure and ocular disease. Zambrano et al. demonstrated significantly higher odds for the presence and increased severity of trachoma when exposed to indoor pollution secondary to cooking fires [104]. Ramirez et al. did not observe any significant association between PM exposure and pterygium [105], while Lee et al. noted a weak yet significant association with PM<sub>10</sub> [106]. No significant association of new pterygium or pterygium recurrence was found with O<sub>3</sub>, NO<sub>2</sub>, or SO<sub>2</sub> [106].

### 3.10. Studies with therapeutic interventions

Only one clinical study assessed in this review was focused on therapeutic management. Antonini et al. investigated the safety and efficacy of daily three times a day administration of topical glyco-phosphoinositol (GPI) eye drops for the treatment of urban syndrome, a mixed condition with features of DED thought to be caused by poor air conditions and the urban environment [107]. Results noted that OSDI score, TBUT, and Schirmer's tear test showed an improvement from patient enrollment to the 1-month endpoint. Of note, the open interventional study only had a treatment arm with no controls nor healthy patients with no history of urban syndrome.

### 3.11. Clinical risk of bias assessment


Risk of bias was assessed using the ROBINS-E tool for observational clinical studies and the RoB 2.0 tool for the single interventional study (Suppl. Tables 5 and 6). Summary findings are reported through the Traffic Light Plots and Summary Plot as represented in Fig. 4a–c. Per ROBINS-E parameters of overall risk of bias assessment, 42% of studies were classified as low, 25% as some concerns, and 33% as high. Domain three had the highest number of risk assessments evaluated as high risk of bias. This is notable as domain three evaluates risk of bias in selection of participants into the study (or analysis); many studies assessed in this review focused on a subset of patients, which may have existing underlying ocular surface dysfunction, distinct from the general population. For the one interventional study evaluated using the RoB 2.0 tool, the overall risk assessment was high.

## 4. Discussion

Overall, this systematic review of both preclinical and clinical studies demonstrates evidence of ocular surface dysfunction resulting from air pollution consisting of a mixture of gaseous substances such as NO<sub>2</sub>, O<sub>3</sub> as well as different types of PM (PM<sub>2.5</sub>, PM<sub>4</sub>, PM<sub>10</sub>, urban PM), diesel exhaust particles, cigarette smoke, and carbon black. While studies varied in their findings of significance, correlation between ocular surface disease and exposure to air pollutants in both normal daily living and environmental disasters is of increased significance. In addition, studies reviewed suggest that exposure to PM and air pollution is not only detrimental during acute environmental disasters or occupational exposures but also from every day exposure given increases in the levels of air pollution parameters measured throughout the years and worsening AQI in some parts of the world [108–111].

One open question that remains is to what extent acute and sub-chronic PM exposures contribute to an increased risk for developing chronic ocular surface disease. Whole body exposure chambers are best suited to model real world exposure and systemic effects of PM exposure that include inflammation, allergic responses, and organ toxicity. Such systemic effects may confound the investigation of ocular effects, which can occur due to local and systemic exposure. Therefore, topical instillation of PM allows for the investigation of mechanism of ocular PM toxicity in the absence of systemic exposure in the preclinical setting. In contrast, whole body exposure could investigate the possible link between neurotoxicity and ocular surface toxicity. Notably, to our knowledge there have been no studies investigating the effects of PM-mediated neurotoxicity on the postganglionic parasympathetic pathway which could result in impaired tear secretion from the lacrimal gland, thereby contributing to ocular surface disease.

Although the exact mechanisms behind the correlation are not fully elucidated, preclinical models implicate pathways related to oxidative stress, inflammation, and apoptosis in PM-induced ocular pathophysiology. Current hypotheses suggest the perturbations may lead to a combination of exaggerated inflammatory response, impaired oxidative stress handling, changes to mucin expression, and allergic and immune responses ultimately leading to ocular surface dysfunction. Given the differences in the composition, type, and origin of PM, the possibility cannot be excluded that different molecular and cellular mechanisms contribute to ocular toxicity. Furthermore, several preclinical studies that reported efficacy of test articles also noted that only limited information was available pertaining to the exact mechanisms of action. Investigation of molecular mechanisms and/or targets of tested interventions can improve the translatability of the studies as well as inform future drug development efforts of targeted therapeutics for PM-



**Fig. 3. Risk of bias assessment of *in vivo* studies.** The SYRCLE's RoB tool was used to evaluate all *in vivo* studies. The following domains were assessed: 1) Was the allocation sequence adequately generated and applied? 2) Were the groups similar at baseline, or were they adjusted for confounders in the analysis? 3) Was the allocation to the different groups adequately concealed? 4) Were the animals randomly housed during the experiment? 5) Were the caregivers and/or investigators blinded from knowledge of which intervention each animal received during the experiment? 6) Were animals selected at random for outcome assessment? 7) Was the outcome assessor-blinded? 8) Were incomplete outcome data adequately addressed? 9) Are reports of the study free of selective outcome reporting? 10) Was the study apparently free of other problems that could result in high risk of bias.?

induced ocular toxicity.

There are several important factors that some studies have in common while others vary and must be taken into careful consideration. *In vitro* and *in vivo* studies utilized different models of environmental pollution exposure that differed in the composition and method/route of administration. For example, the authors obtained environmental pollutants either locally, e.g. by collecting PM from a nearby building, or from commercial vendors. However, different amounts of characterization are publicly available even for commercially sourced PM, further complicating the interpretation of studies. Similarly, the administration model and dosing route had significant heterogeneity between studies, varying from whole-body exposure to topical instillation. For this reason, most studies received medium to low compliance scores for reproducibility in the risk assessment (Fig. 2b). By nature, articles that investigated specific chemicals present in environmental pollutants are more reproducible. However, due to the heterogeneity between sources of pollutants, their use, and the readouts in each study, this systematic review offers a comprehensive overview of models that replicate aspects of the real-world exposure to PM on the ocular surface.

In clinical studies, one major factor that limits comparisons between studies is the method of measuring air pollution exposure. Some studies utilized individualized measurements that provided real-time exposure levels, while others focused on national air quality/meteorological station data. A few studies even built models to combine various data to predict the likely exposure. As expected, the primary concern with national air quality/meteorological data and survey/sociodemographic variables is the potential for misclassification of exposure, which is why the ROBINS-E tool was utilized to compare studies' potential misclassification.

Interestingly, only one study specifically investigated the effect of PM associated with desert sources and at the time of desert storms, but linked the effect of symptoms to the air quality data [112]. Another study reported that participants from the mediterranean climates in the US vs. participants from the subtropical desert climates in the US had better ocular surface health and identified a positive correlation between TBUT measurements and air temperature, humidity, and dew-point [81]. The effects of environmental conditions on the ocular surface and ocular health in general have recently been reviewed in a scoping review [113] and in the TFOS Lifestyle Report [114], respectively.

*In vitro* models primarily employed corneal epithelial or conjunctival epithelial cells as they represent the outermost layers of the eye and the first to come in contact with exposure to the environment; furthermore, they are frequently used in preclinical drug discovery [115,116]. *In vivo* models primarily utilized rodents, because of their low cost and the extensive availability of molecular tools [117]. Ghosh et al. was the singular study to use New Zealand White rabbits [18]. Rabbit models have a larger eye, which allows for a larger exposed ocular surface and the ability to perform more standardized veterinary ophthalmic exams, which are challenging to impossible in rodents. Similarly, Hyun et al. used zebrafish embryos [57]. Zebrafish models have many advantages in providing insights into developmental biology, however, the zebrafish model is not a preferred species for translatability of the ocular surface. The transparent larva allows for sublocalization of any deformations, as seen in the results with severe deformation on epithelial and ocular regions following exposure to fine dust [57,118].

There was also a notable variability in clinical studies assessing the ocular surface disease. Approaches ranged from assessing symptoms per self-report to more detailed and specific clinical examinations. Another consideration is the method of analysis given the wide range of statistical analysis options studies utilized ranging from simple correlation analysis to more complex regression models. While these varying factors provide a unique diversity of studies to assess, they also demonstrate the significant challenge of synthesizing the findings of multiple studies.

**Table 3**  
Clinical studies.

Study	Geographic Location	Study population	Type of Pollutant (s) studied	Method of pollutant exposure measurement	Type of ocular surface disease studied/symptoms	Method of ocular surface disease/symptoms diagnosis or evaluation
Aik et al. [102]	Singapore	Patients diagnosed with conjunctivitis in governmental polyclinics	SO <sub>2</sub> , NO <sub>2</sub> , PM <sub>2.5</sub> , PM <sub>10</sub> , O <sub>3</sub> , CO	Air quality monitoring station data	Acute conjunctivitis	EMR
Almeida et al. [61]	Uberaba, Brazil	Schoolchildren	PM <sub>10</sub> , NO <sub>2</sub> , O <sub>3</sub>	Particle monitor, passive sampling	Tearing, itchy eyes	Questionnaire
Antonini et al. [107]	USA	Patients affected by urban syndrome	N/A (assessed safety and efficacy of GPI topical ophthalmic treatment)	N/A	Urban failure	OSDI, TBUT, Schirmer, fluorescein vital staining according to Oxford score, conjunctival hyperemia score, ocular discomfort symptoms assessed as a score
Arikan et al. [59]	Kutahya, Turkey	Students at a primary school	PM <sub>10</sub> , PM <sub>2.5</sub>	Particles Plus 8306 Handheld Particle Counter	Redness-itching-watering of eyes	Questionnaire
Ashraf et al. [74]	Lahore, Pakistan	Patients presenting with chief complaints of redness, burning, FBS at tertiary care hospitals	Lahore smog: CO, NO <sub>x</sub> , SO <sub>2</sub> , O <sub>3</sub> , VOC, PM <sub>10</sub> , PM <sub>2.5</sub> , TSP	Air quality monitoring station data	Dry eyes, irritation, lid erosion, corneal disease, conjunctival disease	Slit lamp examination and diagnosis by ophthalmologist
Bao et al. [97]	Heifei, China	Patients diagnosed with conjunctivitis in an outpatient setting	NO <sub>2</sub>	Air quality monitoring station data	Conjunctivitis	EMR
Berg et al. [81]	USA	Adults with ocular dryness for at least 6 consecutive months with moderate to severe symptoms	O <sub>3</sub> , CO, NO <sub>2</sub> , NO <sub>x</sub> , NO <sub>y</sub> , SO <sub>2</sub> , PM <sub>2.5</sub>	Air quality monitoring station data	DED	OSDI, TBUT, corneal and conjunctival staining, Schirmer's test
Berra et al. [72]	Buenos Aires, Argentina	Patients with ocular complaints and healthy volunteers	Wildfire smoke, CO, NO <sub>2</sub> , PM	Air quality monitoring station data	Ocular burning, dryness, foreign body sensation, irritation, itching	Questionnaire, ophthalmic examination: bulbar conjunctival hyperemia, corneal fluorescein staining, conjunctival Rose Bengal vital staining, TBUT, Schirmer's test, tear lysozyme concentration, impression cytology
Blinn et al. [66]	Pennsylvania, USA	Residents living in proximity to unconventional oil and gas development	PM <sub>2.5</sub> , CO, NO <sub>x</sub> , VOC, CH <sub>4</sub> , XO <sub>2</sub>	Air quality monitoring station data	Itchy or burning eyes	Questionnaire
Camara et al. [69]	O'ahu, Hawaii	Patients presenting with chief complaint of eye irritation	SO <sub>2</sub> , PM <sub>2.5</sub> , volcanic fog	Air quality monitoring station data	Eye itchiness, foreign body sensation, tearing, burning sensation	Self-reported symptoms, Slit lamp examination findings
Chang et al. [96]	Taiwan	Patients diagnosed with conjunctivitis in an outpatient setting	PM <sub>10</sub> , PM <sub>2.5</sub> , NO <sub>2</sub> , SO <sub>2</sub> , O <sub>3</sub> , CO	Air quality monitoring station data	Conjunctivitis	EMR/ICD-9 codes
Cilluffo et al. [62]	Palermo, Italy	Schoolchildren aged 8-10	NO <sub>2</sub>	Estimated from land use regression model	Burning, itching, dry, red eyes, swollen eyes, sandy feeling in the eyes	Questionnaire
Das et al. [95]	Hyderabad, India	Patients diagnosed with microsporidial keratoconjunctivitis	PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub> , CO	Air quality monitoring station data	Microsporidial keratoconjunctivitis	EMR, assessed by ophthalmologist
Das, Basu [101].	Hyderabad, India	Patients <21 newly diagnosed with allergic eye disease and acute exacerbation of recent onset of symptoms <3 months	PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub> , CO	Air quality monitoring station data	Allergic eye disease	EMR, assessed by ophthalmologist
Galperin et al. [82]	Buenos Aires, Argentina	Sjogren's syndrome patients and healthy volunteers	NO <sub>2</sub>	Individual passive sampler	Sjogren's syndrome, worsening ocular surface disease	OSDI, biomicroscopy, TBUT, Schirmer test, corneal and conjunctival staining, tear lysozyme concentration, impression cytology
Guo et al. [98]	Jinan, China	Patients diagnosed with conjunctivitis in an outpatient setting	NO <sub>2</sub>	Air quality monitoring station data	Conjunctivitis	EMR/ICD-10
Hao et al. [119]	China	DED patients	PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub>	Air quality monitoring station data	DED	OSDI, Schirmer's I test, TMH, TBUT, corneal fluorescein staining, MGD, tear cytokines
Hao, Wan et al. [78]	China	Healthy volunteers aged 20–80 across different regions (coal, steel, oil, urban living)	AQI, PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub>	Air quality monitoring station data	General ocular surface dysfunction	OSDI, lid margin morphology, MG morphology/function, tear meniscus height, Schirmer's test, TBUT, CFS, slit lamp examination of MG; tear film cytokines including IL-1B, IL-6,

(continued on next page)



Table 3 (continued)

Study	Geographic Location	Study population	Type of Pollutant (s) studied	Method of pollutant exposure measurement	Type of ocular surface disease studied/symptoms	Method of ocular surface disease/symptoms diagnosis or evaluation
Ho et al. [90]	Taipei City, Taiwan	First time DED patients	PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , O <sub>3</sub> , CO, CH <sub>4</sub> , NO, NO <sub>2</sub> , Total hydrocarbon, nonmethane hydrocarbon, AQI	Air quality monitoring station data	DED	IL-8, IL-10, IL-17, TNF- $\alpha$ , IFN- $\gamma$ , VEGF, BAFF OSDI, SPEED questionnaire, TBUT, lipid layer thickness, MG morphology, amount of expressive meibomian glands, Schirmer test
Huang et al. [91]	Miami, USA	Veterans	PM <sub>2.5</sub> , PM <sub>10</sub>	Individual passive sampler	DED	OSDI, tear osmolarity, InflammaDry, TBUT, corneal epithelial cell disruption, Schirmer test, eyelid parameters, meibomian gland atrophy, meibum quality Questionnaire
Hwang, Choi et al. [76]	South Korea	Adults	PM <sub>10</sub> , O <sub>3</sub> , NO <sub>2</sub> , SO <sub>2</sub>	Air quality monitoring station data	DED	
Jing et al. [77]	Beijing, China	Healthy elderly volunteers	AQI, PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub>	Air quality monitoring station data	General ocular surface dysfunction/DED	OSDI, slit lamp examination, conjunctival congestion score, conjunctivochalasis grade, TMH, TBUT, corneal fluorescein staining, Schirmer I test, conjunctival impression cytology; VEGF, IL-1B, IL-6, IL-8 in tears
Kaplan et al. [92]	South Florida	Healthy veterans	PM	Collected from Schirmer strips	Ocular surface dysfunction	DEQ5, OSDI, tear osmolarity, InflammaDry®, TBUT, corneal staining, Schirmer test EMR
Khalaila et al. [120]	Beersheba, Israel	Patients diagnosed with conjunctivitis in ophthalmology ER	PM <sub>10</sub> , PM <sub>2.5</sub>	Hybrid model using monitoring station data and mixed model regression	Conjunctivitis	
Kim, Choi et al. [79]	South Korea	DED patients utilizing eye drops	PM <sub>10</sub> , PM <sub>2.5</sub> , O <sub>3</sub>	Air quality monitoring station data	DED	OSDI, TBUT, CFS, Schirmer test
Lai [99].	Taiwan	Patients diagnosed with conjunctivitis in an outpatient setting	CO, NO <sub>2</sub> , SO <sub>2</sub> , O <sub>3</sub> , PM <sub>2.5</sub> , PM <sub>10</sub>	Air quality monitoring station data	Conjunctivitis	EMR/ICD-9 coding
Lee, Choi et al. [106]	South Korea	Adults	PM <sub>10</sub> , O <sub>3</sub> , NO <sub>2</sub> , SO <sub>2</sub>	Air quality monitoring station data	Pterygium	Questionnaire, diagnosis confirmed with history of ocular examination ICD-9 codes
Levanon et al. [93]	Southern Israel	Patients previously diagnosed with vernal keratoconjunctivitis	NO <sub>2</sub> , O <sub>3</sub> , PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub>	Air quality monitoring station data based on participants address	Vernal Keratoconjunctivitis exacerbations	
Majbaudinn et al. [68]	Yonago, Japan	Healthy volunteers	SPM, PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>x</sub>	Air quality monitoring station data	Itchy eyes, teary eyes, bloodshot eyes, bleary eyes	Questionnaire
Malerbi et al. [88]	Sao Paulo, Brazil	Patients presenting to eye clinic	CO, PM <sub>10</sub> , NO <sub>2</sub>	Air quality monitoring station data	Blepharitis	Presence and amount of debris in lid margin, evaluation of meibomian secretion
Matsuda et al. [84]	Sao Paulo, Brazil	Sugarcane workers and residents of neighboring towns	PM <sub>2.5</sub>	Continuous particulate matter laser photometer	Mucus quality and mucin gene expression	MUC5AC, MUC1, MUC16 mRNA levels, goblet cells density from bulbar and tarsal conjunctiva
Matsuda, Bonatti et al. [80]	Sao Paulo, Brazil	Outdoor workers	PM <sub>2.5</sub>	Individual sampler	Lacrimal film alterations	Tear cytokines: IL-2, IL-4, IL-4, IL-10, IFN- $\gamma$
Miyazaki et al. [100]	Japan	Members of Japan Ophthalmologist Association and their family members	NO, NO <sub>2</sub> , NO <sub>x</sub> , SO <sub>2</sub> , PM <sub>2.5</sub> , PM <sub>10</sub>	Air quality monitoring station data	Various forms of allergic ocular disease	Questionnaire
Modi et al. [70]	Miami, USA	Veterans who were abroad in either Iraq or Afghanistan	Incinerated waste	Self-reported exposure	Eye dryness/discomfort	Questionnaire, DEQ5
Moen et al. [85]	Norway	Those living or working near an oil tanker explosion site and “unexposed” volunteers	Black smoke (of mixed pollutants)	Not measured	Tear film stability	NIBUT, SBUT
Norback et al. [64]	Johor Bahru, Malaysia	Junior high schools students	VOC, formaldehyde, NO <sub>2</sub> , CO <sub>2</sub>	Sampling and classroom measurements (not individual)	Eye irritation	Questionnaire


(continued on next page)

Table 3 (continued)

Study	Geographic Location	Study population	Type of Pollutant (s) studied	Method of pollutant exposure measurement	Type of ocular surface disease studied/symptoms	Method of ocular surface disease/symptoms diagnosis or evaluation
Novaes et al. [71]	Sao Paulo, Brazil	Healthy volunteers	NO <sub>2</sub>	Individual passive sampler	Ocular dryness, irritation, heaviness/fatigue, and itching	OSDI, Schirmer test, biomicroscopy, TBUT, corneal and conjunctival staining
Nucci et al. [103]	Milan, Italy	Pediatric conjunctivitis patients presenting to ER or outpatient	PM <sub>2.5</sub> , PM <sub>10</sub>	Air quality monitoring station data	Conjunctivitis of unknown origin	EMR, diagnosis confirmed by ophthalmologist
Prapamontol et al. [63]	Upper Northern Thailand	First grade junior high school students	FeNO, PM <sub>10</sub>	FeNO levels: portal instrument PM10: Air quality monitoring station data	Itching, burning, or irritation of eyes	Questionnaire
Ramirez et al. [105]	Lima, Peru	Workers involved in production and marketing of toilets and ceramics	Exposed for five years or more to PM in an environment with dosimetry values > 10 mg/m <sup>3</sup> for total/inhalable dust and > 3 mg/m <sup>3</sup> for respirable dust	Company data	Pterygium	Primary care physician diagnosis
Recchioni et al. [89]	United Kingdom	Patients with severe ocular surface disease	NO <sub>2</sub> , NO <sub>x</sub> , PM <sub>10</sub> , PM <sub>2.5</sub>	Air quality monitoring station data	Ocular surface disease	OSDI
Singh et al. [65]	Mumbai, India	Exposed group: those living within 1 km radius of Deonar Dumping site	PM <sub>10</sub> , PM <sub>2.5</sub> , CO, O <sub>3</sub> , NO <sub>2</sub> , SO <sub>2</sub> , NH <sub>3</sub>	Air quality monitoring station data	Eye soreness/redness, watering of eyes, itching of eyes	Questionnaire
Sugiyama et al. [60]	Fukoka, Japan	Schoolchildren aged 9-12	PM <sub>2.5</sub>	Air quality monitoring station data	Itchy eyes, watery eyes, sore eyes	Questionnaire
Sundram et al. [121]	Malaysia	Outdoor workers	PM <sub>2.5</sub>	DustTrak DRX Aerosol Monitor installed 1 km radius from each sampling location	Itchy, redness, tearing, swelling of eyes	TOSS
Torricelli et al. [87]	Sao Paulo, Brazil	Healthy male taxi drivers or traffic controllers	NO <sub>2</sub> , PM <sub>2.5</sub>	Individual passive sampler	Ocular dryness, irritation, heaviness, fatigue, and itching	OSDI, Schirmer test, TBUT, vital staining of cornea and conjunctiva, tear osmolarity
Torricelli, Matsuda et al. [86]	Sao Paulo, Brazil	Healthy male taxi drivers or traffic controllers	NO <sub>2</sub> , PM <sub>2.5</sub>	Individual passive sampler	Ocular dryness, irritation, heaviness, fatigue, and itching	OSDI, conjunctival goblet cell assays, MUC5AC mRNA expression, tarsal GC density
Tzortzi et al. [73]	Athens, Greece	Healthy non-smoking adults	PM <sub>2.5</sub> , PM <sub>10</sub>	Continuous measurement during exposure periods	Ocular itchiness, burning, watery eyes, dryness	Questionnaire
Vehof et al. [75]	Netherlands	Healthy volunteers	NO <sub>2</sub> , PM <sub>10</sub> , PM <sub>2.5</sub>	Standardized land-use regression model approach from air quality monitoring station data	DED	Women's Health Study dry eye questionnaire
Wang et al. [83]	Xuzhou, China	Sjogren's syndrome patients and healthy volunteers	AQI	Air quality monitoring station data	Meibomian gland dysfunction	Tear film lipid layer thickness
Watanabe et al. [112]	Japan	Asthma patients	SPM, SO <sub>2</sub> , NO, NO <sub>2</sub>	Air quality monitoring station data	Tearing, itching, mucus, pain	Telephone survey
Zambrano et al. [104]	Kongwa, Tanzania	Children aged 1-9	Indoor cooking fire	Survey/recording of exposure status	Trachoma	Ophthalmic evaluation
Zhang et al. [67]	Beijing, China	Respiratory clinic patients, visitors, graduate students (all naturally exposed to haze)	PM <sub>2.5</sub>	Air quality monitoring station data	Dry eyes, itchy eyes	Questionnaire
Zhou et al. [94]	Guangzhou, China	Children	PM <sub>10</sub> , PM <sub>2.5</sub> , SO <sub>2</sub> , NO <sub>2</sub> , O <sub>3</sub>	Air quality monitoring station data	Allergic conjunctivitis	ICD-10 codes

**Table 3** Abbreviations: EMR: electronic medical record; OSDI: Ocular Surface Disease Index; TBUT: tear break-up time; FBS: foreign body sensation; TMH: tear meniscus height; MG: meibomian gland; MGD: meibomian gland dysfunction; CFS: corneal fluorescein staining; SPEED: Standardized Patient Evaluation of Eye Dryness; DEQ5: Dry Eye Questionnaire-5; NIBUT: non-invasive tear break-up time; SBUT: symptomatic break-up time; VOC: volatile organic compound; DED: dry eye disease.





**Fig. 4.** Risk of bias assessment of clinical studies. (A) For non-randomized clinical studies, the Risk-of-Bias In Non-Randomized Studies of Exposure (ROBINS-E) tool was used for observational studies and (B) the summary plot is provided. (C) The Cochrane Risk-of-bias tool 2.0 (RoB 2.0) was used for randomized controlled trials.

5. Conclusion

This systematic review provides a synthesis of preclinical and clinical studies on the effects of PM and air pollution exposure on the ocular surface. Preclinical studies strongly suggest a correlation between PM exposure and ocular surface dysfunction, primarily due to oxidative stress and inflammatory pathways. Clinical studies have corroborated these findings, demonstrating signs and symptoms similar to those of dry eye disease, conjunctivitis, and allergic eye disease. Though only a few studies have investigated therapeutics for mitigating PM-induced ocular surface damage, there remains an unmet need for the development of future treatments. Collectively, these studies highlight the need for future studies elucidating the multiple molecular mechanisms and targeted therapies for PM-induced ocular toxicity.

CRediT authorship contribution statement

**Sana Iqbal:** Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation. **Abhishek Ramini:** Writing – review & editing, Writing – original draft, Investigation, Data curation. **Simon Kaja:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Declaration of interest statement

The authors report that they have no conflict of interest.

Acknowledgements

This research was funded, in part, by NIH/R24 EY032440 (SK), Illinois Society for the Prevention of Blindness (SK, SI), the Dr. John P. and Therese E. Mulcahy Endowed Professorship in Ophthalmology (SK), and the Richard A. Peritt M.D. Charitable Foundation (SK).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jtos.2024.12.003>.

References

- [1] Organization WH. Household air pollution. 2023.
- [2] Craig JP, et al. TFOS DEWS II definition and classification report. *Ocul Surf* 2017; 15(3):276–83.
- [3] Yang D-L, et al. Indoor air pollution and human ocular diseases: associated contaminants and underlying pathological mechanisms. *Chemosphere* 2023;311: 137037.
- [4] Muruganandam N, et al. Meandered and muddled: a systematic review on the impact of air pollution on ocular health. *Environ Sci Pollut Control Ser* 2023;30 (24):64872–90.
- [5] Craig JP, et al. TFOS Lifestyle report executive summary: a Lifestyle epidemic - ocular surface disease. *Ocul Surf* 2023;30:240–53.
- [6] Dupuis P, et al. A contemporary look at allergic conjunctivitis. *Allergy Asthma Clin Immunol* 2020;16(1).
- [7] Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. *Ophthalmology* 2017;124(11s):S4–S13.
- [8] Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
- [9] Hooijmans CR, et al. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol* 2014;14:43.

- [10] Higgins JP, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- [11] Irvine AR, et al. A systematic review of in vitro models of drug-induced kidney injury. *Current Opinion in Toxicology* 2021;27:18–26.
- [12] Higgins JPT, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). *Environ Int* 2024;186:108602.
- [13] Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
- [14] McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2020. n/a(n/a).
- [15] Akintunde JK, Abioye JB, Ebinama ON. Potential protective effects of naringin on ocular-pulmonary injury induced by PM(10) (wood smoke) exposure by modulation of oxidative damage and acetylcholine esterase activity in a rat model. *Curr Ther Res Clin Exp* 2020;92:100586.
- [16] Fu Q, et al. Airborne particulate matter (PM2.5) triggers autophagy in human corneal epithelial cell line. *Environ Pollut* 2017;227:314–22.
- [17] Fukase S, et al. Pollen shells and soluble factors play non-redundant roles in the development of allergic conjunctivitis in mice. *Ocul Surf* 2021;22:152–62.
- [18] Ghosh AK, et al. Topical porphyrin antioxidant protects against ocular surface pathology in a novel rabbit model for particulate matter-induced dry eye disease. *J Ocul Pharmacol Therapeut* 2022;38(4):294–304.
- [19] Guerra-Flórez DY, et al. In vitro toxicity of fine and coarse particulate matter on the skin, ocular and lung microphysiological cell-culture systems. *Toxicology* 2023;500:153685.
- [20] Hwang M, et al. Traffic-related particulate matter aggravates ocular allergic inflammation by mediating dendritic cell maturation. *J Toxicol Environ Health* 2021;84(16):661–73.
- [21] Hyun SW, et al. Apricot kernel extract and amygdalin inhibit urban particulate matter-induced keratoconjunctivitis sicca. *Molecules* 2019;24(3).
- [22] Kang WS, et al. Long-Term exposure to urban particulate matter on the ocular surface and the incidence of deleterious changes in the cornea, conjunctiva and retina in rats. *Int J Mol Sci* 2020;21(14).
- [23] Kashiwagi K, Iizuka Y. Effect and underlying mechanisms of airborne particulate matter 2.5 (PM2.5) on cultured human corneal epithelial cells. *Sci Rep* 2020;10(1):19516.
- [24] Kim DH, et al. Particulate matter 2.5 promotes inflammation and cellular dysfunction via reactive oxygen species/p38 MAPK pathway in primary rat corneal epithelial cells. *Cutan Ocul Toxicol* 2022;41(4):273–84.
- [25] Ko R, et al. Effects of ambient particulate matter on a reconstructed human corneal epithelium model. *Sci Rep* 2021;11(1):3417.
- [26] Lee HS, et al. Exposure to traffic-related particulate matter 2.5 triggers Th2-dominant ocular immune response in a murine model. *Int J Environ Res Publ Health* 2020;17(8).
- [27] Lee H, et al. The protective effect of topical spermidine on dry eye disease with retinal damage induced by diesel particulate Matter2.5. *Pharmaceutics* 2021;13(9).
- [28] Li J, et al. A mouse dry eye model induced by topical administration of the air pollutant particulate matter 10. *Biomed Pharmacother* 2017;96:524–34.
- [29] Li X, et al. The protective effect of an eye wash solution on the ocular surface damage induced by airborne carbon black exposure. *Cornea* 2020;39(8):1040–7.
- [30] Li X, et al. SIRT1 protects against particulate matter-induced oxidative stress in human corneal and conjunctival epithelial cells. *Invest Ophthalmol Vis Sci* 2022;63(10):19.
- [31] Lyu D, et al. Transcriptomic profiling of human corneal epithelial cells exposed to airborne fine particulate matter (PM(2.5)). *Ocul Surf* 2020;18(4):554–64.
- [32] Niu L, et al. Airborne particulate matter (PM(2.5)) triggers cornea inflammation and pyroptosis via NLRP3 activation. *Ecotoxicol Environ Saf* 2021;207:111306.
- [33] Park SB, et al. Effect of aucubin-containing eye drops on tear hyosecretion and lacrimal gland damage induced by urban particulate matter in rats. *Molecules* 2022;27(9).
- [34] Song SJ, et al. Topical application of liriop platyphylla extract attenuates dry eye syndrome induced by particulate matter. *J Ophthalmol* 2019;2019:1429548.
- [35] Song F, et al. Expression profiles of long noncoding RNAs in human corneal epithelial cells exposed to fine particulate matter. *Chemosphere* 2022;287(Pt 1):131955.
- [36] Tan G, et al. Air pollutant particulate matter 2.5 induces dry eye syndrome in mice. *Sci Rep* 2018;8(1):17828.
- [37] Tang YJ, et al. A murine model of acute allergic conjunctivitis induced by continuous exposure to particulate matter 2.5. *Invest Ophthalmol Vis Sci* 2019;60(6):2118–26.
- [38] Yang Q, et al. Effects of fine particulate matter on the ocular surface: an in vitro and in vivo study. *Biomed Pharmacother* 2019;117:109177.
- [39] Yu D, et al. PM(2.5) exposure increases dry eye disease risks through corneal epithelial inflammation and mitochondrial dysfunctions. *Cell Biol Toxicol* 2023;39(6):2615–30.
- [40] Karakoçak BB, et al. Investigating the effects of stove emissions on ocular and cancer cells. *Sci Rep* 2019;9(1):1870.
- [41] Li J, et al. Dry eye induced by exposure to cigarette smoke pollution: an in vivo and in vitro study. *Free Radic Biol Med* 2020;153:187–201.
- [42] Li X, et al. Comparison of cytotoxicity effects induced by four different types of nanoparticles in human corneal and conjunctival epithelial cells. *Sci Rep* 2022;12(1):155.
- [43] Miao Q, et al. Cigarette smoke induces ROS mediated autophagy impairment in human corneal epithelial cells. *Environ Pollut* 2019;245:389–97.
- [44] Shi K, et al. Necroptosis contributes to airborne particulate matter-induced ocular surface injury. *Toxicology* 2022;470:153140.
- [45] Tau J, et al. Diesel exhaust particles selectively induce both proinflammatory cytokines and mucin production in cornea and conjunctiva human cell lines. *Invest Ophthalmol Vis Sci* 2013;54(7):4759–65.
- [46] Tesone AI, et al. Volcanic ash from Puyehue-Cordón Caulle Volcanic Complex and Calbuco promote a differential response of pro-inflammatory and oxidative stress mediators on human conjunctival epithelial cells. *Environ Res* 2018;167:87–97.
- [47] Lasagni Vitar RM, et al. Evaluation of oxidative stress markers in human conjunctival epithelial cells exposed to diesel exhaust particles (DEP). *Invest Ophthalmol Vis Sci* 2015;56(12):7058–66.
- [48] Lasagni Vitar RM, et al. Diesel exhaust particles (DEP) induce an early redox imbalance followed by an IL-6 mediated inflammatory response on human conjunctival epithelial cells. *Exp Eye Res* 2018;171:37–47.
- [49] Jin M, et al. Phenotypic and transcriptomic changes in the corneal epithelium following exposure to cigarette smoke. *Environ Pollut* 2021;287:117540.
- [50] Kojima T, et al. The effect of Nrf2 knockout on ocular surface protection from acute tobacco smoke exposure: evidence from Nrf2 knockout mice. *Am J Pathol* 2015;185(3):776–85.
- [51] Yang Q, et al. Effects of diesel exhaust particles on the condition of mouse ocular surface. *Ecotoxicol Environ Saf* 2018;163:585–93.
- [52] Jiao J, et al. Atmospheric pollutant black carbon induces ocular surface damage in mice. *Exp Eye Res* 2024;239:109755.
- [53] Maglione GA, et al. Chronic exposure to urban air pollution from Buenos Aires: the ocular mucosa as an early biomarker. *Environ Sci Pollut Res Int* 2019;26(26):27444–56.
- [54] Sendra VG, et al. Polluted air exposure compromises corneal immunity and exacerbates inflammation in acute herpes simplex keratitis. *Front Immunol* 2021;12:618597.
- [55] Lasagni Vitar RM, et al. Urban air pollution induces redox imbalance and epithelium hyperplasia in mice cornea. *Toxicol Appl Pharmacol* 2019;384:114770.
- [56] Li X, et al. The protective effect of a topical mucin secretagogue on ocular surface damage induced by airborne carbon black exposure. *Invest Ophthalmol Vis Sci* 2019;60(1):255–64.
- [57] Hyun J, et al. Detrimental impact of fine dust on zebrafish: investigating a protective agent against ocular-damage using in vitro and in vivo models. *Chemosphere* 2022;293:133602.
- [58] Xiao C, et al. Acute tobacco smoke exposure exacerbates the inflammatory response to corneal wounds in mice via the sympathetic nervous system. *Commun Biol* 2019;2:33.
- [59] Arkan I, Tekin ÖF. The relationship between asthma/allergy symptoms in children and indoor particulate matter in schools. *Cyprus Journal of Medical Sciences* 2023;8:129–35.
- [60] Sugiyama T, et al. Health effects of PM(2.5) sources on children's allergic and respiratory symptoms in Fukuoka, Japan. *Sci Total Environ* 2020;709:136023.
- [61] Lo EA, et al. Influence of urban forest on traffic air pollution and children respiratory health. *Environ Monit Assess* 2020;192(3):175.
- [62] Cilluffo G, et al. Associations of greenness, greyness and air pollution exposure with children's health: a cross-sectional study in Southern Italy. *Environ Health* 2018;17(1):86.
- [63] Prapamontol T, et al. Fractional exhaled nitric oxide (FeNO) in students in Northern Thailand: associations with respiratory symptoms, diagnosed allergy and the home environment. *J Asthma* 2022;59(9):1787–95.
- [64] Norback D, et al. Volatile organic compounds (VOC), formaldehyde and nitrogen dioxide (NO2) in schools in Johor Bahru, Malaysia: associations with rhinitis, ocular, throat and dermal symptoms, headache and fatigue. *Sci Total Environ* 2017;592:153–60.
- [65] Singh SK, et al. Open dumping site and health risks to proximate communities in Mumbai, India: a cross-sectional case-comparison study. *Clinical Epidemiology and Global Health* 2021;9:34–40.
- [66] Blinn HN, et al. Exposure assessment of adults living near unconventional oil and natural gas development and reported health symptoms in southwest Pennsylvania, USA. *PLoS One* 2020;15(8):e0237325.
- [67] Zhang Y, et al. Investigation on the influences of exposure to winter haze (PM2.5) on 301 subjects' respiratory tract. *Traditional Medicine and Modern Medicine* 2018;1(3):219–22.
- [68] Majbaudain A, et al. Association between asian dust-borne air pollutants and daily symptoms on healthy subjects: a web-based pilot study in yonago, Japan. *J Environ Public Health* 2016;2016:8280423.
- [69] Camara JG, Lagunza JK. Ocular findings in volcanic fog induced conjunctivitis. *Hawaii Med J* 2011;70(12):262–5.
- [70] Modi YS, et al. Ocular surface symptoms in veterans returning from operation Iraqi freedom and operation enduring freedom. *Invest Ophthalmol Vis Sci* 2014;55(2):650–3.
- [71] Novaes P, et al. The effects of chronic exposure to traffic derived air pollution on the ocular surface. *Environ Res* 2010;110(4):372–4.
- [72] Berra M, et al. Impact of wildfire smoke in Buenos Aires, Argentina, on ocular surface. *Arq Bras Oftalmol* 2015;78(2):110–4.
- [73] Tzortzi A, et al. Passive exposure of non-smokers to E-Cigarette aerosols: sensory irritation, timing and association with volatile organic compounds. *Environ Res* 2020;182:108963.
- [74] Ashraf A, et al. Smog analysis and its effect on reported ocular surface diseases: a case study of 2016 smog event of Lahore. *Atmos Environ* 2019;198:257–64.

- [75] Vehof J, et al. Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in The Netherlands. *Ocul Surf* 2021;19: 83–93.
- [76] Hwang SH, et al. Potential importance of ozone in the association between outdoor air pollution and dry eye disease in South Korea. *JAMA Ophthalmol* 2016;134(5):503–10.
- [77] Jing D, et al. Evidence of air pollution-related ocular signs and altered inflammatory cytokine profile of the ocular surface in Beijing. *Sci Rep* 2022;12 (1):18359.
- [78] Hao R, et al. The effects of short-term and long-term air pollution exposure on meibomian gland dysfunction. *Sci Rep* 2022;12(1):6710.
- [79] Kim Y, et al. Different adverse effects of air pollutants on dry eye disease: ozone, PM(2.5), and PM(10). *Environ Pollut* 2020;265(Pt B):115039.
- [80] Matsuda M, et al. Lacrimal cytokines assessment in subjects exposed to different levels of ambient air pollution in a large metropolitan area. *PLoS One* 2015;10 (11):e0143131.
- [81] Berg EJ, et al. Climatic and environmental correlates of dry eye disease severity: a report from the dry eye assessment and management (dream) study. *Transl Vis Sci Technol* 2020;9(5):25.
- [82] Galperin G, et al. Impact of environmental pollution on the ocular surface of Sjogren's syndrome patients. *Arq Bras Oftalmol* 2018;81(6):481–9.
- [83] Wang H, et al. Correlation between air quality index and tear film lipid layer thickness: comparison between patients with sjogren's syndrome and with meibomian gland dysfunction. *Curr Eye Res* 2023;48(5):447–55.
- [84] Matsuda M, et al. Occupational effect of sugarcane biomass burning on the conjunctival mucin profile of harvest workers and residents of an adjacent town - a Brazilian panel study. *Exp Eye Res* 2020;190:107889.
- [85] Moen BE, et al. Can air pollution affect tear film stability? A cross-sectional study in the aftermath of an explosion accident. *BMC Publ Health* 2011;11:235.
- [86] Torricelli AA, et al. Effects of ambient levels of traffic-derived air pollution on the ocular surface: analysis of symptoms, conjunctival goblet cell count and mucin 5AC gene expression. *Environ Res* 2014;131:59–63.
- [87] Torricelli AA, et al. Correlation between signs and symptoms of ocular surface dysfunction and tear osmolality with ambient levels of air pollution in a large metropolitan area. *Cornea* 2013;32(4):e11–5.
- [88] Malerbi FK, et al. Ambient levels of air pollution induce clinical worsening of blepharitis. *Environ Res* 2012;112:199–203.
- [89] Recchioni A, et al. The impact of the first United Kingdom COVID-19 lockdown on environmental air pollution, digital display device use and ocular surface disease symptomatology amongst shielding patients. *Sci Rep* 2022;12(1):20820.
- [90] Ho WT, Chiu CY, Chang SW. Low ambient temperature correlates with the severity of dry eye symptoms. *Taiwan J Ophthalmol* 2022;12(2):191–7.
- [91] Huang A, et al. Association of the indoor environment with dry eye metrics. *JAMA Ophthalmol* 2020;138(8):867–74.
- [92] Kaplan C, et al. Human ocular surface particulate composition in the clinical versus home environment. *Cornea* 2019;38(10):1266–72.
- [93] Levanon E, et al. Air pollution and meteorological conditions significantly associated with vernal keratoconjunctivitis exacerbations. *Invest Ophthalmol Vis Sci* 2023;64(10):37.
- [94] Zhou J, et al. Size-specific particulate matter and outpatient visits for allergic conjunctivitis in children: a time-stratified case-crossover study in Guangzhou, China. *Environ Sci Pollut Res Int* 2023;30(12):33949–59.
- [95] Das AV, Basu S. Temporal trend of microsporidial keratoconjunctivitis and correlation with environmental and air pollution factors in India. *Indian J Ophthalmol* 2021;69(5):1089–94.
- [96] Chang CJ, et al. Relationship between air pollution and outpatient visits for nonspecific conjunctivitis. *Invest Ophthalmol Vis Sci* 2012;53(1):429–33.
- [97] Bao N, et al. Association between short-term exposure to ambient nitrogen dioxide and the risk of conjunctivitis in Hefei, China: a time-series analysis. *Environ Res* 2021;195:110807.
- [98] Guo H, et al. Short-term exposure to nitrogen dioxide and outpatient visits for cause-specific conjunctivitis: a time-series study in Jinan, China. *Atmos Environ* 2021;247:118211.
- [99] Lai YH. Relationship between air pollution and outpatient visits for nonspecific conjunctivitis in Taiwan. *Electronic Journal of General Medicine* 2019;16(4).
- [100] Miyazaki D, et al. Air pollution significantly associated with severe ocular allergic inflammatory diseases. *Sci Rep* 2019;9(1):18205.
- [101] Das AV, Basu S. Environmental and air pollution factors affecting allergic eye disease in children and adolescents in India. *Int J Environ Res Publ Health* 2021; 18(11).
- [102] Aik J, et al. The burden of acute conjunctivitis attributable to ambient particulate matter pollution in Singapore and its exacerbation during South-East Asian haze episodes. *Sci Total Environ* 2020;740:140129.
- [103] Nucci P, et al. Pediatric conjunctivitis and air pollution exposure: a prospective observational study. *Semin Ophthalmol* 2017;32(4):407–11.
- [104] Zambrano AI, et al. Exposure to an indoor cooking fire and risk of trachoma in children of kongwa, Tanzania. *PLoS Neglected Trop Dis* 2015;9(6):e0003774.
- [105] Ramirez CA, et al. Ocular exposure to particulate matter and development of pterygium: a case-control study. *Int J Occup Environ Med* 2018;9(4):163–9.
- [106] Lee KW, et al. Outdoor air pollution and pterygium in Korea. *J Kor Med Sci* 2017; 32(1):143–50.
- [107] Antonini M, et al. Ocular surface failure in urban syndrome. *J Clin Med* 2021;10 (14).
- [108] Clay K, Muller NZ, Wang X. Recent increases in *air pollution: Evidence and Implications for mortality*. *Rev Environ Econ Pol* 2021;15(1):154–62.
- [109] Ren X, et al. Modeling past and future spatiotemporal distributions of airborne allergenic pollen across the contiguous United States. *Frontiers in Allergy* 2022;3.
- [110] Ravindiran G, et al. Impact of air pollutants on climate change and prediction of air quality index using machine learning models. *Environ Res* 2023;239(Pt 1): 117354.
- [111] Brumberg HL, Karr CJ. Ambient air pollution: health hazards to children. *Pediatrics* 2021;147(6).
- [112] Watanabe M, et al. Influence of asian desert dust on lower respiratory tract symptoms in patients with asthma over 4 years. *Yonago Acta Med* 2012;55(2): 41–8.
- [113] Wong YL, et al. Impacts of climate change on ocular health: a scoping review. *J Clim Change and Health* 2024;15:100296.
- [114] Alves M, et al. TFOS Lifestyle Report: impact of environmental conditions on the ocular surface. *Ocul Surf* 2023;29:1–52.
- [115] Reichl S. Cell culture models of the human cornea - a comparative evaluation of their usefulness to determine ocular drug absorption in-vitro. *J Pharm Pharmacol* 2008;60(3):299–307.
- [116] García-Posadas L, et al. A new human primary epithelial cell culture model to study conjunctival inflammation. *Invest Ophthalmol Vis Sci* 2013;54(10): 7143–52.
- [117] Huang W, et al. Animal models of dry eye disease: useful, varied and evolving. *Exp Ther Med* 2021;22(6):1394 (Review).
- [118] Rosa JGS, Lopes-Ferreira M, Lima C. An overview towards zebrafish larvae as a model for ocular diseases. *Int J Mol Sci* 2023;24(6).
- [119] Hao R, et al. Impact of air pollution on the ocular surface and tear cytokine levels: a multicenter prospective cohort study. *Front Med* 2022;9:909330.
- [120] Khalaila S, et al. Association between ambient temperature, particulate air pollution and emergency room visits for conjunctivitis. *BMC Ophthalmol* 2021;21 (1):100.
- [121] Sundram TKM, et al. Impacts of particulate matter (PM(2.5)) on the health status of outdoor workers: observational evidence from Malaysia. *Environ Sci Pollut Res Int* 2022;29(47):71064–74.